PROSCA/BLADDR 2022 | Polygenic risk scores for the early detection of prostate cancer

Eric Klein, MD, Glickman Urology & Kidney Institute, Cleveland, OH, reflects on the use of molecular profiling for the early detection of prostate cancer, highlighting polygenic risk scores to determine lifetime risk and subsequent screening strategies that can be employed. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR 2022) in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.